Ravi A. Madan, Clinical researcher at the National Cancer Institute, shared a post on X:
“Lots of zeal in oncology for new tech to detect recurrence (eg ctDNA, molecular imaging).
Sobering however to recall that it remains unclear if early detection improves outcomes. This presumption remains unclear in Prostate Cancer w/PSMA and PSA.”
Title: Routine Surveillance for Cancer Metastases – Does It Help or Harm Patients?
Authors: H. Gilbert Welch, Lesly A. Dossett
Read the Full Article.
Other articles featuring Ravi A. Madan on OncoDaily.
